Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARQ 531 + VLS-101 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARQ 531 | ARQ531|ARQ-531|Nemtabrutinib|MK-1026|MK 1026|MK1026 | BTK inhibitor 37 | ARQ 531 is an ATP-competitive BTK inhibitor with activity against wild-type BTK and BTK C481S, which may inhibit migration and viability of tumor cells (PMID: 30093506, PMID: 31992353). | |
VLS-101 | VLS 101|VLS101|Zilovertamab Vedotin|MK 2140|MK2140|MK-2140 | ROR1 Antibody 7 | VLS-101 is an antibody-drug conjugate (ADC) comprising a ROR1-targeted antibody linked to monomethyl auristatin E (MMAE), which delivers the drug to ROR1-expressing tumor cells, potentially resulting in increased apoptosis and decreased tumor growth (Blood (2019) 134 (Supplement_1): 2856). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05458297 | Phase II | VLS-101 ARQ 531 + VLS-101 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination With Nemtabrutinib (MK-1026) in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Recruiting | USA | TUR | SWE | POL | ITA | ISR | IRL | GBR | EST | ESP | DEU | CZE | CAN | BRA | 7 |